CDK9 inhibitors for the treatment of castration resistant prostate cancer.
Prostate cancer is the most frequently diagnosed cancer in men and is incurable. It is caused by the over-production of the proteins that prevent cancer cells from undergoing programmed cell death. Inhibiting the activity of an enzyme called cyclin-dependent kinase 9 (CDK9) can block the expression of these cancer related proteins, leading to cancer cell death. This project is developing novel and highly selective small molecule inhibitors of CDK9 for treating prostate cancer.
What we aim to achieve
This project will evaluate CDK9 as an effective target and provide CDK9 inhibitors as potential drug candidates for treatment of prostate cancer.
What are the next steps and milestones for your research?
A novel series of CDK9 inhibitor compounds will be synthesized and assessed using our established screening cascade, which comprises biochemical and cell-based assays. Promising leads possessing favourable bio-pharmaceutical properties will be further evaluated for anti-prostate cancer efficacy.
What motivates you to pursue cancer research?
My research career has been devoted to the discovery of effective and safe medicine for treating cancers. It is extremely satisfying to be involved in research that could one-day benefit millions afflicted by cancer.
My message to supporters:
We have expertise in multiple disciplines of science and understand the value of intellectual creativity and originality. Despite all the benefits and advantages, drug discovery cannot succeed in isolation. The path to a new drug is long and costly. We need public, private and industry partnerships to make sure our drug molecules can deliver its successes to the clinic.